Curis, Inc. · NASDAQ:CRIS

Curis — Investor Presentation (December 2020)

34 slides from Curis's investor presentation, December 2020

  1. Slide 1: Corporate Presentation

    Corporate Presentation NASDAQ: CRIS

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements

    Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,”

  3. Slide 3: Curis Mission & Strategy

    Curis Mission & Strategy Developing the New Generation of Targeted Cancer Drugs Innovation Execution Mission Strategy Work relentlessly to develop Select the right targets innovative and differentiated Design the right drugs therapeutics that improve the lives Study the right patients of cancer pati

  4. Slide 4: Company Overview

    Company Overview Investment Curis seeks to develop novel, first-in-class, cancer therapeutics Thesis that we believe have significant potential in areas of unmet patient need CA-4948: first-in-class inhibitor of IRAK4 in oncology Robust There are no drugs currently approved for IRAK4 inhibition in o

  5. Slide 5: Evolution of Curis

    Evolution of Curis Progressing through Clinical Studies on the Path to Potential Registration 2019 2020 2021 Initial Clinical Data Expand Clinical Opportunities Registrational Strategy  Report initial Ph1 data for CA-4948 in  Report expanded Ph1 data for CA-4948 study  Initiate Combination Study

  6. Slide 6: Pipeline

    Pipeline All Curis programs are novel, first-in-class PRE-CLINICAL CLINICAL MARKETED Dose Clinical Indication Proof of Principle Safety Pivotal Commercial Optimization Activity Heme Malignancies CA-4948* MYD88/TLR-altered IRAK4 Lymphoma (NHL) CA-4948* IRAK4L-expressing IRAK4 Leukemia (AML/MDS) Fimep

  7. Slide 7: CA-4948: IRAK4 Targeted Program in NHL

    IRAK4 Targeted Program in NHL CA-4948: In development for treatment of cancers driven by NF-kB and the TLR/Myddosome 7

  8. Slide 8: CA-4948 Overview: First-in-Class Inhibitor of IRAK4 in Oncology

    CA-4948 Overview First-in-Class Inhibitor of IRAK4 in Oncology Affinity Profile Kinase Kd (nM) Designed to be best-in-class IRAK4 23 IRAK4 inhibitor1 IRAK1 12,000 • First-in-class IRAK4 inhibitor in cancer IRAK2 >20,000 • Specific malignancies in Lymphoma are characterized by overactivity of NF-kB a

  9. Slide 9: Novel Mechanism of Action for Addressing NF-κB

    CA-4948 In Nov 2020, Novel Mechanism of Action for Addressing NF-κB the NCI selected CA-4948 and entered into a CRADA agreement with Curis to conduct non-clinical BTK and TLR are parallel pathways and clinical studies of CA-4948 as a potential anti-cancer agent and primary independent activators of

  10. Slide 10: CA-4948 in Lymphoma: Trial Design

    CA-4948 in Lymphoma Trial Design Data cut-off: 23Nov2020 Overall Baseline Characteristics of Ph1 Patients (N=31) Male 26 (84%) Study Objectives Female 5 (16%) Primary: Safety and tolerability Secondary: Pharmacokinetic (PK) profile, preliminary anti-cancer activity Median Age 69yrs Histology Diffuse

  11. Slide 11: Two Potential Biomarkers Identified

    CA-4948 in Lymphoma Two Potential Biomarkers Identified ❷ Is NF-κB activity driven by the TLR/myddosomal axis? BTK Pathway TLR Pathway MYD88 Mutation B cell TLR1 TLR2 Genetic alteration of MYD88 at baseline TLR4 TLR5 receptor TLR6 causes constitutive activation of the myddosome and is a driver of NF

  12. Slide 12: Early Biomarker Data from Phase 1 Patients

    CA-4948 in Lymphoma Early Biomarker Data from Phase 1 patients This clinical study is ongoing, more data are needed to confirm these potential biomarkers p-p50 Biomarker May Support Patient Selection NF-κB phospho-p50 NF-κB phospho-p50 protein expression at baseline • Patients whose tumors do not ex

  13. Slide 13: Anti-Cancer Activity and Dose Response in a Waldenström's Patient

    CA-4948 in Lymphoma Anti-Cancer Activity and Dose Response in a Patient with Waldenströms Macroglobulinemia (WM) Note: This WM patient is one of the two patients in the Ph1 study who tested positive for MYD88 Demonstrated Anti-Cancer Activity Objective Response observed at 300mg BID (RP2D) Demonstra

  14. Slide 14: 300mg BID (RP2D) Offered Best Balance of Tolerability and Activity

    CA-4948 in Lymphoma In Updated Ph1 Data, 300mg BID (RP2D) Offered Best Balance of Tolerability and Anti-Cancer Activity Change in Tumor Burden for 13 Evaluable Patients (200mg BID+) • Clear Single Agent Anti-Cancer Activity at RP2D 50% Tumor reduction 6 of 7 pts in a heavily pretreated population (4

  15. Slide 15: 300mg BID (RP2D) Tolerability and Anti-Cancer Activity

    CA-4948 in Lymphoma In Updated Ph1 Data, 300mg BID (RP2D) Offered Best Balance of Tolerability and Anti-Cancer Activity Patients Dosed at Recommended Ph2 Dose • Clear Single Agent Anti-Cancer Activity at RP2D (300mg BID) Tumor reduction 6 of 7 pts in a heavily pretreated population (4 prior lines of

  16. Slide 16: 2021 Plan: Combination Study (CA-4948 + ibrutinib)

    CA-4948 in Lymphoma 2021 Plan: Initiate Clinical Study in Combination Therapy (CA-4948 + ibrutinib) Anti-Cancer Activity in Monotherapy and Combination Therapy in MYD88-altered DLBCL preclinical model (OCI-Ly10) 1500 vehicle Mechanism of Action Supports Combination 1200 • CA-4948 potentially offers

  17. Slide 17: CA-4948 in Lymphoma (planned combination study)

    CA-4948 in Lymphoma (planned combination study) Trial Design Study Objectives Primary: Safety and tolerability of CA-4948 in combination with ibrutinib Secondary: Pharmacokinetic (PK) profile, preliminary anti-cancer activity Study Population • Relapsed/Refractory disease • Histopathologically confi

  18. Slide 18: IRAK4 Targeted Program in AML/MDS

    IRAK4 Targeted Program in AML/MDS CA-4948: In development for treatment of cancers driven by IRAK4-L 18

  19. Slide 19: Landscape of Disease Targets in AML/MDS

    CA-4948 in AML/MDS Landscape of Disease Targets in AML/MDS • Non-targeted therapies administered in monotherapy have historically % of Patient Disease Driver Population provided limited clinical benefit, especially in relapsed/refractory patients IRAK4-L > 50%1 FLT3 25-30%2 • Targeted therapies (e.g

  20. Slide 20: IRAK4-L is a Novel Target in AML/MDS

    CA-4948 in AML/MDS IRAK4-L is a Novel Target in AML/MDS Specific Genetic Mutations Drive the Expression of the Long Isoform of IRAK4 (IRAK4-L) Oncogenic IRAK4-L, which is driven by spliceosome mutations (incl. SF3B1 and U2AF1), is preferentially expressed >50% of AML/MDS patients IRAK4-L is Oncogeni

  21. Slide 21: CA-4948 in AML/MDS: Trial Design

    CA-4948 in AML/MDS Trial Design Data cut-off: 23Nov2020 Study Objectives Overall Primary: Maximum tolerated dose and recommended Phase 2 dose Baseline Characteristics of Ph1 Patients (N=6) Secondary: Pharmacokinetic (PK) profile, preliminary anti-cancer activity Male (%) 5 (83%) Female (%) 1 (17%) S

  22. Slide 22: Monotherapy Anti-Cancer Activity Observed in Early Ph1 Data

    CA-4948 in AML/MDS Monotherapy Anti-Cancer Activity Observed in Early Ph1 Data 40% AML 35% hrMDS • 1st patient dosed in Q3 2020 30% • Consistent reduction of Marrow Blasts across population (6 patients) Bone Marrow Blast Percentage 300mg 25% 300mg • 2 patients have achieved Marrow CR 20% Blasts Blas

  23. Slide 23: VISTA Targeted Program in Solid Tumors

    VISTA Targeted Program in Solid Tumors CI-8993: In development for treatment of cancers driven by VISTA-mediated Immune Suppression 23

  24. Slide 24: CI-8993 Overview

    CI-8993 Overview In Development for VISTA Expressing and Infiltrated Cancers Curis is the first to advance an oral small molecule checkpoint inhibitor into the clinic Profile • First-in-class monoclonal antibody antagonist of VISTA Value Proposition • Composition-of-matter IP extends into 2034 • Pat

  25. Slide 25: VISTA is an Important Checkpoint Regulator

    CI-8993 Target Background VISTA is an Important Checkpoint Regulator • CTLA-4, PD-1, and VISTA are the three main players in controlling checkpoint blockade • VISTA controls early T cell activation events • Blockade of VISTA will allow for an expanded T cell response against tumors Eltanbouly et al.

  26. Slide 26: Role of VISTA in Immune Suppression in the TME

    CI-8993 Target Background Role of VISTA in Immune Suppression in the Tumor Microenvironment (TME) Blocking PD-1 VISTA Blocking VISTA activates T cells re-suppresses T cells1 re-activates T cells2 ❶ ❷ ❸ ❹ Normal Immune Suppression Temporary Immune Activation VISTA-mediated Immune Suppression Alleviat

  27. Slide 27: CI-8993 Preclinical Data

    CI-8993 Preclinical Data Preclinical anti-cancer activity demonstrated in both monotherapy & combination therapy Monotherapy Combination Therapy Anti-VISTA inhibited tumor growth Anti-VISTA inhibited xenograft growth in B16ova melanoma model1 in checkpoint resistant CT26 model2 Control n=14 100% Day

  28. Slide 28: CI-8993 Clinical Plan

    CI-8993 Clinical Plan Phase 1 dose escalation study design Patient Population • Patients with advanced refractory solid tumors Curis Design for Ph1 Dose Escalation Study (includes mesothelioma, melanoma, NSCLC, TNBC) Treatment 0.15mg/kg Level 2 Level 3 Higher Doses Continue dose escalation • Bi-week

  29. Slide 29: Targeted Programs in Heme Malignancies: Fimepinostat

    Targeted Programs in Heme Malignancies Fimepinostat: In development for treatment of MYC-altered cancers 29

  30. Slide 30: Fimepinostat Overview

    Fimepinostat Overview In Development for Patients with MYC-Altered Cancers PI3Ki Profile Mechanism #1 HDACi Mechanism #2 The HDAC component The PI3K component Suppresses Enhances • First-in-class drug candidate with demonstrated anti-cancer activity as a MYC transcription2 MYC destruction2 Value Pro

  31. Slide 31: Fimepinostat Clinical Anti-Cancer Activity in MYC-Altered Cancers

    Fimepinostat Overview Clinical Anti-Cancer Activity in Patients with MYC-Altered Cancers in Ph1 and Ph2 Studies Deep Responses in MYC-altered patients (49 evaluable patients; 60 ITT patients) Deep Responses CR/PR SD/PD • 8 complete responses (CR); 6 partial responses (PR) • 2 patients able to procee

  32. Slide 32: Company Summary

    Company Summary Investment Curis seeks to develop novel, first-in-class, cancer therapeutics Thesis that we believe have significant potential in areas of unmet patient need CA-4948: first-in-class inhibitor of IRAK4 in oncology Robust There are no drugs currently approved for IRAK4 inhibition in on

  33. Slide 33: Leadership Team

    Curis Leadership Team Rachel Blasbalg James Dentzer Christine Guertin Robert Martell Head, Human Resources President & CEO Head, Regulatory Head, R&D Mark Noel Reinhard von Roemeling Raul Soikes Nancy Soohoo William Steinkrauss Head, Intellectual Property Head, Clinical Development Head, Portfolio M

  34. Slide 34: End of Corporate Presentation

    End of Corporate Presentation NASDAQ: CRIS

Curis — Investor Presentation (December 2020) on 6ix